0 5 Human human JJ 6 12 T-cell T-cell NNP 13 21 leukemia leukemia NN 22 27 virus virus NN 28 32 type type NN 33 34 I i CD 35 38 Tax Tax NNP 39 49 associates associate VBZ 50 54 with with IN 55 58 and and CC 59 61 is be VBZ 62 72 negatively negatively RB 73 82 regulated regulate VBN 83 85 by by IN 86 89 the the DT 90 98 NF-kappa NF-kappa NNP 99 101 B2 b2 NN 102 106 p100 p100 NN 107 111 gene gene NN 112 119 product product NN 119 120 : : : 121 133 implications implication NNS 134 137 for for IN 138 143 viral viral JJ 144 151 latency latency NN 151 152 . . . 154 159 Human human JJ 160 166 T-cell T-cell NNP 167 175 leukemia leukemia NN 176 181 virus virus NN 182 186 type type NN 187 188 I i CD 189 190 ( ( ( 190 196 HTLV-I HTLV-I NNP 196 197 ) ) ) 198 200 is be VBZ 201 204 the the DT 205 214 etiologic etiologic JJ 215 220 agent agent NN 221 223 of of IN 224 227 the the DT 228 233 adult adult JJ 234 240 T-cell t-cell NN 241 249 leukemia leukemia NN 249 250 , , , 251 253 an an DT 254 264 aggressive aggressive JJ 265 268 and and CC 269 274 often often RB 275 280 fatal fatal JJ 281 291 malignancy malignancy NN 292 294 of of IN 295 304 activated activate VBN 305 310 human human JJ 311 314 CD4 cd4 NN 315 316 T t NN 317 322 cells cell NNS 322 323 . . . 324 330 HTLV-I HTLV-I NNP 331 338 encodes encode VBZ 339 341 an an DT 342 351 essential essential JJ 352 358 40-kDa 40-kda JJ 359 366 protein protein NN 367 373 termed term VBN 374 377 Tax Tax NNP 378 382 that that WDT 383 386 not not RB 387 391 only only RB 392 406 transactivates transactivate VBZ 407 410 the the DT 411 415 long long JJ 416 424 terminal terminal JJ 425 431 repeat repeat NN 432 434 of of IN 435 439 this this DT 440 450 retrovirus retrovirus NN 451 454 but but CC 455 459 also also RB 460 467 induces induce VBZ 468 470 an an DT 471 476 array array NN 477 479 of of IN 480 488 cellular cellular JJ 489 494 genes gene NNS 494 495 . . . 496 508 Tax-mediated tax-mediated JJ 509 523 transformation transformation NN 524 526 of of IN 527 528 T t NN 529 534 cells cell NNS 535 541 likely likely RB 542 550 involves involve VBZ 551 554 the the DT 555 566 deregulated deregulate VBN 567 577 expression expression NN 578 580 of of IN 581 588 various various JJ 589 597 cellular cellular JJ 598 603 genes gene NNS 604 608 that that WDT 609 617 normally normally RB 618 626 regulate regulate VBP 627 637 lymphocyte lymphocyte NN 638 644 growth growth NN 645 653 produced produce VBN 654 656 by by IN 657 664 altered altered JJ 665 673 activity activity NN 674 676 of of IN 677 684 various various JJ 685 695 endogenous endogenous JJ 696 700 host host NN 701 714 transcription transcription NN 715 722 factors factor NNS 722 723 . . . 724 726 In in IN 727 737 particular particular JJ 737 738 , , , 739 742 Tax Tax NNP 743 745 is be VBZ 746 753 capable capable JJ 754 756 of of IN 757 767 modulating modulate VBG 768 771 the the DT 772 782 expression expression NN 783 785 or or CC 786 794 activity activity NN 795 797 of of IN 798 805 various various JJ 806 810 host host NN 811 824 transcription transcription NN 825 832 factors factor NNS 832 833 , , , 834 843 including include VBG 844 851 members member NNS 852 854 of of IN 855 858 the the DT 859 867 NF-kappa NF-kappa NNP 868 873 B/Rel B/Rel NNP 874 877 and and CC 878 886 CREB/ATF CREB/ATF NNP 887 895 families family NNS 895 896 , , , 897 899 as as RB 900 904 well well RB 905 907 as as IN 908 911 the the DT 912 920 cellular cellular JJ 921 928 factors factor NNS 929 934 HEB-1 heb-1 NN 935 938 and and CC 939 945 p67SRF p67SRF NNP 945 946 . . . 947 949 An an DT 950 960 additional additional JJ 961 975 distinguishing distinguishing NN 976 990 characteristic characteristic JJ 991 993 of of IN 994 1000 HTLV-I HTLV-I NNP 1001 1010 infection infection NN 1011 1013 is be VBZ 1014 1017 the the DT 1018 1026 profound profound JJ 1027 1032 state state NN 1033 1035 of of IN 1036 1041 viral viral JJ 1042 1049 latency latency NN 1050 1054 that that WDT 1055 1057 is be VBZ 1058 1065 present present JJ 1066 1068 in in IN 1069 1080 circulating circulate VBG 1081 1088 primary primary JJ 1089 1097 leukemic leukemic JJ 1098 1099 T t NN 1100 1105 cells cell NNS 1105 1106 . . . 1107 1109 In in IN 1110 1114 this this DT 1115 1120 study study NN 1120 1121 , , , 1122 1124 we we PRP 1125 1136 demonstrate demonstrate VBP 1137 1141 that that IN 1142 1148 HTLV-I HTLV-I NNP 1149 1152 Tax Tax NNP 1153 1156 can can MD 1157 1167 physically physically RB 1168 1177 associate associate VB 1178 1182 with with IN 1183 1187 p100 p100 NN 1187 1188 , , , 1189 1192 the the DT 1193 1200 product product NN 1201 1203 of of IN 1204 1207 the the DT 1208 1219 Rel-related rel-related JJ 1220 1228 NF-kappa NF-kappa NNP 1229 1231 B2 b2 NN 1232 1236 gene gene NN 1236 1237 , , , 1238 1242 both both CC 1243 1245 in in IN 1246 1257 transfected transfecte VBN 1258 1263 cells cell NNS 1264 1267 and and CC 1268 1270 in in IN 1271 1286 HTLV-I-infected htlv-i-infected JJ 1287 1295 leukemic leukemic JJ 1296 1302 T-cell t-cell NN 1303 1308 lines line NNS 1308 1309 . . . 1310 1321 Furthermore furthermore RB 1321 1322 , , , 1323 1326 the the DT 1327 1335 physical physical JJ 1336 1347 interaction interaction NN 1348 1350 of of IN 1351 1354 Tax Tax NNP 1355 1359 with with IN 1360 1364 p100 p100 NN 1365 1370 leads lead VBZ 1371 1373 to to TO 1374 1377 the the DT 1378 1388 inhibition inhibition NN 1389 1391 of of IN 1392 1403 Tax-induced tax-induced JJ 1404 1414 activation activation NN 1415 1417 of of IN 1418 1421 the the DT 1422 1428 HTLV-I HTLV-I NNP 1429 1432 and and CC 1433 1438 human human JJ 1439 1455 immunodeficiency immunodeficiency NN 1456 1461 virus virus NN 1462 1466 type type NN 1467 1468 1 1 CD 1469 1473 long long JJ 1474 1482 terminal terminal JJ 1483 1490 repeats repeat NNS 1490 1491 , , , 1492 1502 reflecting reflect VBG 1503 1516 p100-mediated p100-mediated JJ 1517 1528 cytoplasmic cytoplasmic JJ 1529 1542 sequestration sequestration NN 1543 1545 of of IN 1546 1549 the the DT 1550 1558 normally normally RB 1559 1568 nuclearly nuclearly RB 1569 1578 expressed express VBD 1579 1582 Tax Tax NNP 1583 1590 protein protein NN 1590 1591 . . . 1592 1594 In in IN 1595 1603 contrast contrast NN 1603 1604 , , , 1605 1606 a a DT 1607 1613 mutant mutant NN 1614 1616 of of IN 1617 1620 Tax Tax NNP 1621 1625 that that WDT 1626 1637 selectively selectively RB 1638 1643 fails fail VBZ 1644 1646 to to TO 1647 1655 activate activate VB 1656 1663 nuclear nuclear JJ 1664 1672 NF-kappa NF-kappa NNP 1673 1674 B B NNP 1675 1685 expression expression NN 1686 1690 does do VBZ 1691 1694 not not RB 1695 1704 associate associate VB 1705 1709 with with IN 1710 1714 p100 p100 NN 1714 1715 . . . 1716 1717 ( ( ( 1717 1725 ABSTRACT abstract NN 1726 1735 TRUNCATED truncated VBN 1736 1738 AT at IN 1739 1742 250 250 CD 1743 1748 WORDS words NNS 1748 1749 ) ) )